Table 1.
Analyses of racial-ethnic differences in use of antipsychotic agents with high metabolic risk after a U.S. Food and Drug Administration advisory
| Estimate of olanzapine use over timea | Risk of receiving olanzapine
|
Black versus white
|
Hispanic versus white
|
||||
|---|---|---|---|---|---|---|---|
| White | Black | Hispanic | Risk difference | 95% CI | Risk difference | 95% CI | |
| Institute of Medicine definition of health care disparity (rank-and-replace method) | |||||||
| Preadvisory period (Jan 2001–Jan 2003) | .40 | .40 | .57 | .00 | −.03 to .03 | .17 | .13 to .20 |
| Early advisory period (Feb 2003–Nov 2003) | .35 | .35 | .49 | −.01 | −.03 to .02 | .14 | .11 to .17 |
| Advisory period (Dec 2003–Aug 2004) | .25 | .25 | .35 | .00 | −.02 to .02 | .10 | .08 to .12 |
| Initial postadvisory period (Sept 2004–Mar 2005) | .17 | .17 | .24 | .00 | −.02 to .01 | .07 | .05 to .08 |
| PDL/CATIE/dementia warning (April 2005–Sept 2005) | .08 | .08 | .11 | .00 | −.01 to .00 | .03 | .02 to .04 |
| Post-PDL/CATIE/dementia warning (Oct 2005–Dec 2006) | .07 | .07 | .09 | .00 | −.00 to .00 | .03 | .01 to .04 |
| Unadjusted estimate | |||||||
| Preadvisory period (Jan 2001–Jan 2003) | .41 | .40 | .56 | .00 | −.03 to .02 | .16 | .13 to .19 |
| Early advisory period (Feb 2003–Nov 2003) | .35 | .35 | .49 | .00 | −.03 to .03 | .14 | .11 to .17 |
| Advisory period (Dec 2003–Aug 2004) | .25 | .25 | .35 | .00 | −.03 to .03 | .10 | .07 to .13 |
| Initial postadvisory period (Sept 2004–March 2005) | .17 | .17 | .24 | .00 | −.03 to .03 | .07 | .03 to .11 |
| PDL/CATIE/dementia warning (April 2005–Sept 2005) | .08 | .08 | .11 | .00 | −.03 to .03 | .03 | .00 to .06 |
| Post-PDL/CATIE/dementia warning (Oct 2005–Dec 2006) | .07 | .07 | .09 | .00 | −.03 to .03 | .03 | −.01 to .06 |
| Residual direct effect definition | |||||||
| Preadvisory period (Jan 2001–Jan 2003) | .40 | .39 | .49 | −.01 | −.04 to .02 | .08 | .05 to .11 |
| Early advisory period (Feb 2003–Nov 2003) | .35 | .34 | .42 | −.01 | −.05 to .02 | .06 | .03 to .11 |
| Advisory period (Dec 2003–Aug 2004) | .25 | .24 | .30 | −.01 | −.04 to .03 | .05 | .02 to .08 |
| Initial postadvisory period (Sept 2004–March 2005) | .17 | .17 | .21 | −.01 | −.04 to .03 | .03 | −.01 to .07 |
| PDL/CATIE/dementia warning (April 2005–Sept 2005) | .08 | .08 | .09 | .00 | −.04 to .03 | .01 | −.02 to .05 |
| Post-PDL/CATIE/dementia warning (Oct 2005–Dec 2006) | .07 | .06 | .08 | .00 | −.03 to .03 | .01 | −.02 to .05 |
a
PDL/CATIE, temporary implementation of a preferred drug list (PDL) in Florida Medicaid (July 2005) and the publication of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) results